Author: SAMUELSON G Article type: Narrative Review Field: Cardiology, Cardiothoracic Surgery, Transplant Medicine Language: English Repository status: Research manuscript and supporting materials
Heart transplantation remains the definitive treatment for carefully selected patients with advanced, irreversible heart failure who have exhausted conventional medical, interventional, and mechanical treatment options.
This research paper provides a structured review of the clinical, surgical, immunological, ethical, and technological aspects of heart transplantation. It examines recipient and donor selection, organ allocation, surgical techniques, rejection mechanisms, immunosuppressive therapy, postoperative surveillance, complications, long-term outcomes, mechanical circulatory support, xenotransplantation, regenerative medicine, precision medicine, and emerging artificial-intelligence applications.
The paper is intended as a scholarly synthesis for students, researchers, clinicians, and readers interested in contemporary heart-transplant practice.
Heart Transplantation: Contemporary Practice, Outcomes, Challenges, and Future Directions
SAMUELSON G Independent Researcher
Heart transplantation is an established treatment for selected patients with end-stage heart disease who remain severely symptomatic despite guideline-directed medical therapy, device therapy, revascularisation, and other appropriate interventions. Advances in donor selection, recipient evaluation, operative technique, immunosuppressive treatment, infection prevention, rejection surveillance, and long-term follow-up have substantially improved outcomes.
This review examines the complete heart-transplant pathway, including clinical indications, contraindications, donor-recipient matching, organ preservation, orthotopic and heterotopic transplantation, immunological rejection, maintenance immunosuppression, endomyocardial biopsy, biomarker-based surveillance, primary graft dysfunction, infection, cardiac allograft vasculopathy, renal dysfunction, malignancy, and psychosocial care.
The paper also discusses major unresolved challenges, including donor-organ scarcity, inequitable access, sensitisation, chronic rejection, immunosuppressive toxicity, graft durability, and the need for lifelong surveillance. Emerging developments in donation after circulatory death, ex vivo organ perfusion, mechanical circulatory support, xenotransplantation, regenerative medicine, molecular diagnostics, donor-derived cell-free DNA, gene-expression profiling, artificial intelligence, and precision immunosuppression may reshape future practice.
Heart transplantation continues to offer substantial survival and quality-of-life benefits, but its long-term success depends on careful candidate selection, multidisciplinary care, ethical organ allocation, accurate rejection monitoring, and continued scientific innovation.
Heart transplantation, cardiac transplantation, heart failure, donor heart, organ allocation, orthotopic transplantation, rejection, immunosuppression, endomyocardial biopsy, cardiac allograft vasculopathy, mechanical circulatory support, xenotransplantation, regenerative medicine, precision medicine.
This research paper aims to:
- explain the clinical role of heart transplantation;
- describe recipient and donor selection;
- compare orthotopic, biatrial, bicaval, and heterotopic surgical techniques;
- review immune rejection and immunosuppressive treatment;
- summarise postoperative surveillance and long-term care;
- examine major early and late complications;
- discuss ethical, legal, and organ-allocation considerations;
- evaluate emerging technologies and future research directions.
The historical development and current clinical importance of heart transplantation.
The chambers, valves, great vessels, coronary circulation, cardiac output, and haemodynamic principles relevant to transplantation.
Major indications include:
- advanced heart failure refractory to optimal treatment;
- dilated cardiomyopathy;
- ischaemic cardiomyopathy;
- selected congenital heart diseases;
- restrictive cardiomyopathy;
- selected valvular cardiomyopathies;
- refractory ventricular arrhythmias;
- selected cases requiring combined organ transplantation.
The paper reviews absolute and relative contraindications, including severe irreversible pulmonary vascular disease, uncontrolled infection, active malignancy, advanced irreversible extracardiac disease, poor adherence, and major psychosocial limitations.
Candidate assessment includes:
- clinical and functional evaluation;
- right-heart catheterisation;
- pulmonary vascular resistance assessment;
- renal and hepatic evaluation;
- infectious-disease screening;
- malignancy screening;
- immunological testing;
- psychosocial evaluation;
- frailty and nutritional assessment.
The manuscript discusses:
- blood-group compatibility;
- donor-recipient size matching;
- donor age and cardiac function;
- ischaemic time;
- infectious and malignancy risks;
- human leukocyte antigen considerations;
- sensitisation and donor-specific antibodies;
- ethical allocation and urgency-based prioritisation.
The paper compares:
- biatrial orthotopic transplantation;
- bicaval orthotopic transplantation;
- heterotopic transplantation;
- recipient cardiectomy;
- donor-heart preparation;
- atrial and caval anastomoses;
- pulmonary-artery anastomosis;
- aortic anastomosis;
- reperfusion and graft assessment.
Bicaval orthotopic transplantation is generally preferred because it better preserves atrial geometry and may reduce postoperative tricuspid regurgitation and rhythm-related complications compared with older biatrial methods.
The manuscript reviews:
- hyperacute rejection;
- acute cellular rejection;
- antibody-mediated rejection;
- chronic rejection;
- donor-specific antibodies;
- complement activation;
- T-cell and B-cell responses;
- graft endothelial injury.
Common treatment categories include:
- calcineurin inhibitors;
- antimetabolites;
- corticosteroids;
- mammalian target of rapamycin inhibitors;
- interleukin-2 receptor antagonists;
- anti-thymocyte globulin;
- antibody-targeted and plasma-based therapies for selected rejection cases.
A commonly used maintenance platform consists of tacrolimus, mycophenolate, and corticosteroids, with subsequent treatment adapted to rejection risk, renal function, infection, cardiac allograft vasculopathy, malignancy risk, and adverse effects.
Surveillance methods include:
- endomyocardial biopsy;
- echocardiography;
- haemodynamic assessment;
- donor-specific antibody monitoring;
- gene-expression profiling;
- donor-derived cell-free DNA;
- cardiac magnetic resonance imaging in selected settings.
Postoperative management includes:
- haemodynamic monitoring;
- rhythm surveillance;
- graft-function assessment;
- renal protection;
- antimicrobial prophylaxis;
- therapeutic drug monitoring;
- rehabilitation;
- vaccination;
- metabolic risk management;
- psychosocial support.
- primary graft dysfunction;
- bleeding;
- acute rejection;
- infection;
- renal dysfunction;
- arrhythmias;
- vasoplegia;
- right-ventricular failure.
- cardiac allograft vasculopathy;
- chronic kidney disease;
- hypertension;
- diabetes mellitus;
- dyslipidaemia;
- recurrent or opportunistic infection;
- malignancy;
- chronic graft dysfunction;
- frailty and reduced functional capacity.
The role of ventricular assist devices and temporary mechanical support is discussed in relation to:
- bridge to transplantation;
- bridge to candidacy;
- bridge to recovery;
- destination therapy;
- management of primary graft dysfunction.
Paediatric considerations include congenital heart disease, previous surgical reconstruction, donor-size limitations, growth, development, medication adherence, transition to adult care, and long-term graft durability.
The manuscript examines:
- informed consent;
- organ scarcity;
- allocation fairness;
- transplantation tourism;
- organ trafficking;
- deceased donation;
- donation after circulatory death;
- determination of death;
- conflicts of interest;
- access disparities;
- responsible communication of research findings.
Future developments reviewed in the paper include:
- ex vivo heart perfusion;
- improved donor-heart preservation;
- donation after circulatory death;
- molecular rejection monitoring;
- artificial intelligence;
- precision immunosuppression;
- genomic and proteomic biomarkers;
- bioengineered cardiac tissue;
- stem-cell therapies;
- xenotransplantation;
- gene-edited donor organs.
The repository includes the following figures:
- Anatomy of the Human Heart and Major Indications for Heart Transplantation
- Global Trends in Heart Transplantation
- Patient Survival After Heart Transplantation
- Orthotopic Heart Transplantation: Standard Bicaval Surgical Steps
- Immunosuppression in Heart Transplantation
- Early and Late Complications After Heart Transplantation
- Orthotopic and Heterotopic Heart-Transplantation Techniques
- Immunosuppression and Rejection-Surveillance Algorithm
- Timeline of Post-Heart-Transplant Care
Figures containing clinical statistics must be linked to their original registry, trial, guideline, or observational-study sources. Conceptual diagrams are labelled as author-created scientific illustrations.
Artificially generated images should not be presented as direct clinical photographs, operative records, or original experimental evidence.
Manuscript tables include:
- Indications and contraindications for heart transplantation.
- Components of recipient evaluation.
- Donor-selection and matching criteria.
- Comparison of biatrial, bicaval, and heterotopic transplantation.
- Classification of cardiac allograft rejection.
- Major immunosuppressive medicines and adverse effects.
- Early and late complications after transplantation.
- Recommended post-transplant surveillance by phase.
- Emerging technologies in heart transplantation.
- Ethical and policy challenges in organ allocation.
heart-transplant-research/
│
├── README.md
├── LICENSE
├── CITATION.cff
├── manuscript/
│ ├── heart-transplant-research-paper.docx
│ └── heart-transplant-research-paper.pdf
│
├── figures/
│ ├── figure-01-heart-anatomy.png
│ ├── figure-02-global-trends.png
│ ├── figure-03-survival.png
│ ├── figure-04-surgical-steps.png
│ ├── figure-05-immunosuppression.png
│ ├── figure-06-complications.png
│ ├── figure-07-transplant-techniques.png
│ ├── figure-08-rejection-algorithm.png
│ └── figure-09-post-transplant-timeline.png
│
├── tables/
│ ├── tables.docx
│ └── tables.xlsx
│
├── references/
│ ├── references.bib
│ └── references-vancouver.txt
│
└── supplementary-material/
└── figure-legends-and-abbreviations.pdf
This manuscript is structured as a narrative review and scholarly synthesis.
The research process should include:
- searching major medical and scientific databases;
- prioritising peer-reviewed systematic reviews, clinical guidelines, registry reports, consensus statements, and landmark studies;
- evaluating the relevance and reliability of each source;
- comparing findings across studies;
- separating established clinical evidence from emerging or experimental approaches;
- citing all numerical claims and clinical recommendations;
- documenting limitations and areas of uncertainty.
Databases and sources include:
- PubMed;
- MEDLINE;
- Cochrane Library;
- International Society for Heart and Lung Transplantation;
- World Health Organization;
- national transplant registries;
- organ-allocation authorities;
- major cardiology and transplantation journals.
| Abbreviation | Meaning |
|---|---|
| ACR | Acute cellular rejection |
| AMR | Antibody-mediated rejection |
| ATG | Anti-thymocyte globulin |
| CAV | Cardiac allograft vasculopathy |
| CMV | Cytomegalovirus |
| CNI | Calcineurin inhibitor |
| DSA | Donor-specific antibody |
| dd-cfDNA | Donor-derived cell-free DNA |
| DCD | Donation after circulatory death |
| ECMO | Extracorporeal membrane oxygenation |
| EMB | Endomyocardial biopsy |
| GEP | Gene-expression profiling |
| HLA | Human leukocyte antigen |
| ICU | Intensive care unit |
| IVC | Inferior vena cava |
| IVIG | Intravenous immunoglobulin |
| LVAD | Left ventricular assist device |
| MCS | Mechanical circulatory support |
| mTOR | Mammalian target of rapamycin |
| PGD | Primary graft dysfunction |
| SVC | Superior vena cava |
Heart transplantation remains the most effective definitive treatment for appropriately selected patients with advanced and irreversible heart failure. Its success results from coordinated progress in recipient selection, donor assessment, organ allocation, surgical technique, immunosuppression, rejection surveillance, infection prevention, rehabilitation, and long-term multidisciplinary care.
The bicaval orthotopic technique has become the preferred surgical approach in many centres because it preserves atrial anatomy more effectively than the older biatrial method. Tacrolimus-based combination immunosuppression remains a central treatment platform, although therapy must be adjusted continuously according to rejection risk, renal function, infection, malignancy, cardiac allograft vasculopathy, and medication toxicity.
Despite improved outcomes, heart transplantation remains limited by donor scarcity, chronic rejection, graft vasculopathy, renal dysfunction, infection, malignancy, unequal access, and the burden of lifelong immunosuppression. Emerging strategies such as ex vivo organ perfusion, donation after circulatory death, non-invasive molecular surveillance, precision immunosuppression, artificial intelligence, regenerative medicine, and genetically modified xenografts may expand the donor pool and improve long-term graft survival.
Future progress will depend on rigorous clinical research, transparent organ-allocation systems, equitable access, reliable long-term data, responsible innovation, and continued collaboration among transplant specialists, researchers, patients, donor families, regulatory authorities, and healthcare systems.
SAMUELSON G was responsible for the conception, literature synthesis, manuscript preparation, organisation of tables and figures, interpretation of published evidence, and final approval of the manuscript.
No external funding was received for this research.
The author declares no conflict of interest.
This manuscript is a literature-based review and does not report original research involving human participants or animals. Formal institutional ethics approval was therefore not required.
Not applicable.
No original patient-level dataset was generated or analysed. All information was derived from publicly available scientific literature, clinical guidelines, registry reports, and other cited sources.
The author acknowledges the clinicians, researchers, organ donors, donor families, transplant recipients, registry teams, and healthcare professionals whose contributions have advanced the field of heart transplantation.
Citation:
Samuelson G. Heart transplantation: contemporary practice, outcomes, challenges, and future directions. 2026.
A CITATION.cff file added to the repository after the manuscript title, publication date, DOI, version, and repository URL have been finalised.
This repository contains a research manuscript intended for scholarly communication.
The manuscript should not be described as peer-reviewed unless it has completed an independent journal peer-review process. A repository upload, GitHub release, Zenodo deposit, or preprint publication does not by itself constitute peer-reviewed journal publication.
This repository is intended for research and educational purposes only. It does not provide medical advice, diagnosis, or treatment recommendations for individual patients.
Clinical decisions concerning heart transplantation must be made by qualified transplant professionals using current guidelines, institutional protocols, multidisciplinary assessment, and patient-specific clinical information.
A suitable licence is selected according to the intended use.
- CC BY 4.0 for the research manuscript and original figures;
- MIT License only for software, scripts, or code;
- All rights reserved when redistribution is not permitted.
Do not relicence third-party figures, data, or copyrighted materials without permission.
Author: SAMUELSON G Role: Independent Researcher
For academic correspondence, collaboration, corrections, or citation updates, use the contact information provided in the final published manuscript.
Before public release:
- verify every reference;
- cite every numerical statistic;
- confirm that figure labels are medically accurate;
- remove unsupported or illustrative clinical percentages;
- identify conceptual figures clearly;
- check journal and repository copyright requirements;
- disclose artificial-intelligence assistance where required;
- obtain permission for any third-party material;
- ensure that no confidential patient information is included.